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Abstract 
Objective: To describe the epidemiology, long-term outcomes and temporal trends in 
mortality in ambulatory patients with chronic heart failure (HF) with reduced (HFrEF), mid-
range (HFmrEF) or preserved ejection fraction (HFpEF) from three European countries. 
Methods: We identified 10,312 patients from the Norwegian HF Registry and the HF 
registries of the universities of Heidelberg, Germany, and Hull, UK. Patients were classified 
according to baseline left ventricular ejection fraction (LVEF) and time of enrolment (period 1: 
1995-2005 vs. period 2: 2006-2015). Predictors of mortality were analysed by use of 
univariable and multivariable Cox regression analyses. 
Results: Among 10,312 patients with stable HF, 7,080 (68.7%), 2,086 (20.2%), and 1,146 
(11.1%) were classified as having HFrEF, HFmrEF, or HFpEF, respectively. A total of 4,617 
(44.8%) patients was included in period 1, and 5,695 (55.2%) patients were included in 
period 2. Baseline characteristics significantly differed with respect to type of HF and time of 
enrolment. During a median follow-up of 66 (33-105) months, 5,297 patients (51.4%) died. In 
multivariable analyses, survival was independent of LVEF category (p>0.05), while mortality 
was lower in period 2 as compared to period 1 (HR 0.81, 95% CI 0.72-0.91, p<0.001). 
Significant predictors of all-cause mortality regardless of HF category were increasing age, 
NYHA functional class, NT-proBNP, and use of loop diuretics. 
Conclusion: Ambulatory HF patients stratified by LVEF represent different phenotypes. 
However, after adjusting for a wide range of covariates, long-term survival is independent of 
LVEF category. Outcome significantly improved during the last two decades irrespective from 
type of HF. 
Words: 250 
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Key questions 
What is already known about this subject? 
Heart failure (HF) is a major cause of morbidity and mortality in Europe. Patients who suffer 
from HF with reduced ejection fraction (HFrEF) differ from those with preserved ejection 
fraction (HFpEF) with respect to demographical characteristics, comorbidities and response 
to therapies. Little is known about the epidemiology and characteristics of patients with HF 
with mid-range ejection fraction (HFmrEF). 
What does this study add? 
The present study describes the epidemiology, long-term outcomes and temporal trends in 
mortality in ambulatory patients with chronic HFrEF, HFmrEF or HFpEF from three European 
countries. 
How might this impact on clinical practice? 
Patients with HFmrEF have distinct demographical and clinical characteristics. Although 
crude mortality is lower compared to patients with HFrEF, outcome is independent from HF 
category at a given NT-proBNP level. Therefore, measurement of NT-proBNP is crucial for 
risk stratification of HF patients.   
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Introduction 
According to heart failure (HF) guidelines, HF may be classified with respect to left 
ventricular ejection fraction (LVEF) into HF with reduced (HFrEF) or preserved ejection 
fraction (HFpEF) [1]. While HFrEF has been generally defined as LVEF <40%, LVEF 
thresholds for the definition of HFpEF have varied in clinical trials from >40% to >50%, 
leaving the LVEF range of 40-50% as a “grey area”. The 2016 European Society of 
Cardiology (ESC) HF guidelines have recently defined HF with mid-range LVEF (HFmrEF) to 
accommodate such patients [1]. Patients with HFrEF differ from those with HFpEF: they tend 
to be younger, are more likely to be male, to have ischaemic HF and to respond to therapies 
targeted at neurohormonal activation; whereas patients with HFpEF are older, more likely to 
be women, to be in atrial fibrillation and to have antecedent hypertension. Little is known 
about the epidemiology and characteristics of patients with HFmrEF [2, 3, 4, 5].  
Pharmacological and device therapies have substantially improved survival in patients with 
HFrEF over recent decades [1, 6, 7, 8], whereas no specific treatment has yet been shown to 
reduce mortality in patients with HFmrEF or HFpEF [1, 2]. As patients with HFmrEF have 
frequently been excluded from randomised trials, prospective outcome data in this patient 
population are scarce [2].  
The ESC HF Long-Term (ESC-HF-LT) Registry has recently reported data on clinical 
characteristics and outcomes of ≈9,000 patients with HF (2,212 patients with HFmrEF) [3]. 
This register, however, does not include patients from Norway, the United Kingdom (UK) or 
Germany, and outcome data are restricted to 12 months follow-up. In the present 
manuscript, we present characteristics of 11,028 HF patients from HF registers in Norway, 
UK, and Germany, extended to long-term outcome, and with respect to HF category and 
period of enrolment.   
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Methods 
Databases 
Patient data were extracted from three European HF registries: 
The Norwegian HF Registry was initiated in October 2000 and patients were enrolled from 
the outpatient clinics of 27 recruiting hospitals well distributed in all regions of Norway, 
ranging in size and scope from small community to large university hospitals. Patient data 
were registered at first contact with the patient (visit 1), after individual optimization of HF 
treatment (visit 2), and again 6 months after visit 2 (visit 3). The participating centres 
recorded their data using a web-based database, and mortality data were obtained at regular 
intervals from the National Statistics Bureau, Statistics Norway. For the purpose of the 
present manuscript, patient data registered at the last available visit were analysed. 
Patients who attended the community HF clinics of the University of Heidelberg, Germany, 
and the University of Hull, UK, for evaluation of HF were offered inclusion into the local HF 
registries. The HF registries were initiated in December 1995 and March 2001, respectively. 
Since both university hospitals are providers of secondary and tertiary care, the registries 
reflect a broad representation of patients of their respective regions. Patients were included 
after stabilization of both clinical status and medication. Determination of survival status and 
follow-up were performed by scheduled visits to the outpatient clinics, by telephone calls 
either to the patients’ homes or to their physicians, or by electronic hospital records. For the 
purpose of the present analysis, patients were censored as “alive” at the date of this last 
contact. All surviving patients were followed for ≥6 months. All-cause mortality was the 
primary endpoint of the present study. 
Recruitment was prospective and continuous for each database and centre [9]. All patients 
gave their written informed consent for data storage and evaluation. The study conformed to 
the principles outlined in the Declaration of Helsinki and was approved by the local ethics 
committees.  
6 
 
The diagnosis of HF was established according to guidelines on the basis of typical 
symptoms and signs consistent with the diagnosis associated with an objective abnormality 
of cardiac structure or function on echocardiography, cardiac magnetic resonance imaging, 
or left heart catheterisation. In patients with normal or mildly reduced LVEF, evidence of a 
relevant structural heart disease (e.g. left ventricular hypertrophy or left atrial enlargement) 
and/or diastolic dysfunction was required. Baseline characteristics included medical history, 
physical examination, LVEF, blood chemistry, and medication. Medication was at the 
discretion of the referring physician.  Glomerular filtration rate (GFR) was estimated using the 
Chronic Kidney Disease Epidemiology Collaboration formula [10].  
Statistical analysis 
Patient data were stratified according to their LVEF and time of enrolment into the HF 
registry. In order to examine changes in therapy and outcome over time, we divided the 
patients into two cohorts: those recruited between 1995 and 2005 (period 1); and those 
recruited between 2006 and 2015 (period 2). 2005 was used as a cut-off for three reasons: 1. 
to give two similar sized populations, 2. to compare outcomes between two decades, 3. new 
HF guidelines were introduced in 2005. HFrEF, HFmrEF, and HFpEF were defined according 
to the 2016 ESC HF guidelines as LVEF <40%, 40-49%, and ≥50%, respectively [1].   
All tests are two-tailed and a P-value of less than 5% was regarded as being statistically 
significant. Variables are presented as mean±standard deviation, median (interquartile 
range), or number (percentages (%)) as appropriate. Chi-squared tests were used to 
compare categorical variables. To test for significant differences between two groups, the 
Man-Whitney-U test or Student’s t-test were used. To test for significant differences between 
three or more groups, the Kruskal-Wallis test or analyses of variance (ANOVA) tests were 
used where appropriate. Differences in survival with respect to class of HF and/or time period 
were analysed using Cox proportional hazard models and displayed using the Kaplan-Meier 
method. 
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All variables that were statistically significant in univariable analyses by LVEF group or time 
period were included in multivariable Cox regression models with backwards elimination to 
identify predictors for all-cause mortality. A significance level of 5% was required to allow a 
variable both to be entered into and to stay in the multivariable models. Statistics were 
calculated using MedCalc® version 18.11.3 (MedCalc Software bvba, Ostend, Belgium). 
 
Results 
Characteristics 
From December 1995 to November 2015, a total of 11,028 ambulatory patients with stable 
chronic HF was enrolled into the three registries. Of these, 7,080 patients (64.2%) were 
classified as having HFrEF, 2,086 patients (18.9%) as having HFmrEF, and 1,146 patients 
(10.4%) as having HFpEF. In 716 (6.5%) patients, no information on LVEF was available. 
They were therefore excluded from further analyses. The distribution of HF categories in the 
three registries is shown in supplemental table 1. 
Baseline characteristics and treatment significantly differed between patients with HFrEF, 
HFmrEF, or HFpEF, respectively (Tables 1-2).  
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Table 1: Baseline characteristics of HF patients with respect to type of HF 
 All patients  
(n = 10,312) 
HFrEF  
(n = 7,080) 
HFmrEF  
(n = 2,086) 
HFpEF 
(n = 1,146) 
p-value 
Age, years 66.7 ± 13.4 66.6 ± 12.6 67.3 ± 14.1 
65.9 ± 
16.8 
0.02 
Female, n (%) 2,738 (26.6) 
1,674 
(23.6) 
610 (29.2) 454 (39.6) <0.001 
BMI, kg/m² 27.2 ± 5.3 26.9 ± 5.2 27.9 ± 5.5 27.0 ± 5.3 <0.001 
SBP, mmHg 125 ± 22 123 ± 22 129 ± 23 128 ± 22 <0.001 
HR, 1/min 70 ± 14 71 ± 14 69 ± 14 69 ± 13 <0.001 
Sinus rhythm, n (%) 6,405 (67.7) 
4,429 
(68.1) 
1,287 (66.4) 689 (67.5) 0.39 
LVEF, % 34 ± 12 27 ± 7 43 ± 3 57 ± 7 <0.001 
Cause of HF, n (%)     <0.001 
ischaemic 5,161 (53.8) 
3,781 
(58.1) 
1,067 (53.9) 313 (28.6)  
non-ischaemic 4,424 (46.2) 
2,731 
(41.9) 
911 (46.1) 782 (71.4)  
NYHA class, n (%)     <0.001 
I/II 6,767 (66.5) 
4,504 
(64.5) 
1,470 (71.8) 783 (69.5)  
III/IV 3,403 (33.5) 
2,481 
(35.5) 
579 (28.1) 343 (30.5)  
Comorbidity, n (%)      
Diabetes mellitus 2,128 (20.6) 
1,458 
(20.7) 
456 (21.9) 214 (18.7) 0.11 
Hypertension 4,209 (40.8) 2,595 967 (46.4) 647 (56.7) <0.001 
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(36.8) 
COPD/ asthma 1,232 (11.9) 885 (12.6) 229 (11.0) 118 (10.3) 0.03 
Smoker, n (%)* 3,430 (37.3) 
2,285 
(36.5) 
788 (41.3) 357 (34.7) <0.001 
Sodium, mmol/L 139 ± 4 139 ± 4 140 ± 3 140 ± 3 0.11 
Potassium, mmol/L 4.4 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 4.3 ± 0.5 <0.001 
NTproBNP, pg/mL 
1,008 
(305-2,605) 
1,301 
(482-
3,169) 
652 
(180-1,759) 
316 
(100-
1,302) 
<0.001 
eGFR, 
ml/min/1.73m² 
67 (49-86) 66 (49-84) 68 (50-88) 71 (50-92) <0.001 
Time of enrolment, 
n (%) 
    <0.001 
Period 1  4,617 (44.8) 
3,325 
(47.0) 
850 (40.7) 442 (38.6)  
Period 2  5,695 (55.2) 
3,755 
(53.0) 
1,236 (59.3) 704 (61.4)  
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection 
fraction; HFpEF, heart failure with preserved ejection fraction; BMI, body mass index; SBP, systolic blood pressure; 
HR, heart rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; COPD, chronic 
obstructive pulmonary disease; NTproBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular 
filtration rate using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula; period 1: 1995-
2005, period 2: 2006-2015. *former or active smokers. Significant p-values are written in italics. 
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Table 2: Treatment of HF patients with respect to type of HF 
Treatment 
All patients  
(n = 10,312) 
HFrEF  
(n = 7,080) 
HFmrEF  
(n = 2,086) 
HFpEF 
(n = 1,146) 
p-
value 
ACEI, n (%) 7,219 (70.0) 5,131 (72.6) 1,430 (68.7) 658 (57.5) <0.001 
Captopril 174 (2.4) 138 (2.7) 21 (1.5) 15 (2.3) 0.03 
Enalapril 1,135 (15.7) 836 (16.3) 178 (12.4) 121 (18.4) <0.001 
Lisinopril 906 (12.6) 637 (12.4) 197 (13.8) 72 (10.9) 0.17 
Ramipril 4,794 (66.4) 3,377 (65.8) 985 (68.9) 432 (65.7) 0.09 
Trandolapril 12 (0.2) 8 (0.2) 4 (0.3) 0 (0.0) 0.33 
Other 197 (2.7) 134 (2.6) 45 (3.1) 18 (2.7) 0.55 
ARB, n (%) 1,915 (18.6) 1,304 (18.5) 376 (18.1) 235 (20.6) 0.36 
ACEI and/or ARB, n 
(%) 
8,867 (86.0) 6,231 (88.5) 1,763 (84.9) 873 (76.4) <0.001 
ACEI/ARB dose 
equivalent, % 
50 (25-100) 75 (50-100) 50 (50-100) 50 (50-100) <0.001 
Beta-blocker, n (%) 8,482 (82.3) 5,992 (84.8) 1,662 (79.8) 828 (72.5) <0.001 
Bisoprolol 1,425 (16.8) 943 (15.7) 320 (19.3) 162 (19.6) <0.001 
Carvedilol 2,275 (26.8) 1,728 (28.8) 391 (23.5) 156 (18.8) <0.001 
Metoprolol 
succinate 
4,208 (49.6) 2,989 (49.9) 783 (47.1) 436 (52.7) 0.03 
Nebivolol 160 (1.8) 83 (1.4) 42 (2.5) 35 (4.2) <0.001 
Other  414 (4.9) 249 (4.2) 126 (7.6) 39 (4.7) <0.001 
Beta-blocker dose 
equivalent, % 
50 (13-75) 50 (25-100) 50 (25-75) 50 (25-75) 0.10 
MRA, n (%) 3,098 (30.0) 2,360 (33.4) 508 (24.4) 230 (20.1) <0.001 
Loop diuretics, n (%) 7,288 (70.7) 5,387 (76.1) 1,266 (60.7) 635 (55.4) <0,001 
Loop diuretic dose, 40 (0-80) 40 (40-80) 40 (40-80) 40 (40-80) 0.36 
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mg furosemide 
Anticoagulants, n 
(%) 
4,492 (43.6) 3,271 (46.3) 790 (37.9) 431 (37.7) <0.001 
ASA, n (%) 4,411 (42.8) 3,063 (43.3) 936 (44.9) 412 (36.0) <0.001 
Statin, n (%) 5,784 (56.1) 4,038 (57.1) 1,209 (58.0) 537 (46.9) <0.001 
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection 
fraction; HFpEF, heart failure with preserved ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; ASA, Acetylsalicyl acid. Significant p-
values are written in italics. 
 
 
A total of 4,617 patients (44.8%) was included into the HF registries in period 1, whereas 
5,695 patients (55.2%) were enrolled in period 2. Baseline characteristics and treatment of 
patients with respect to time periods are shown in Tables 3 -4. Baseline characteristics with 
respect to HF category and time of enrolment are presented in Supplemental tables 2-4. 
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Table 3: Baseline characteristics of HF patients with respect to time of enrolment into the 
heart failure registries (period 1: 1995-2005, period 2: 2006-2015) 
 All patients  
(n = 10,312) 
Period 1  
(n = 4,617) 
Period 2  
(n = 5,695) 
p-value 
Age, years 66.7 ± 13.4 68.1 ± 12.5 65.5 ± 14.0 <0.001 
Female, n (%) 2,738 (26.6) 1,213 (27.4) 1,525 (26.8) 0.56 
BMI, kg/m² 27.2 ± 5.3 26.9 ± 5.2 27.4 ± 5.4 <0.001 
SBP, mmHg 125 ± 22 126 ± 23 124 ± 21 <0.001 
HR, 1/min 70 ± 14 71 ± 15 70 ± 14 <0.001 
Sinus rhythm, n (%) 6,405 (67.7) 2,719 (68.5) 3,686 (64.7) <0.001 
LVEF, % 34 ± 12 33 ± 12 34 ± 12 <0.001 
Type of HF, n (%)     
HFrEF 7,080 (70.7) 3,325 (72.0) 3,755 (65.9) <0.001 
HFmrEF 2,086 (18.9) 850 (18.4) 1,236 (21.7) <0.001 
HFpEF 1,146 (10.4) 442 (9.6) 704 (12.4) <0.001 
Cause of HF, n (%)    <0.001 
ischaemic 5,161 (53.8) 2,533 (60.1) 2,628 (48.9)  
non-ischaemic 4,424 (46.2) 1,682 (39.9) 2,742 (51.1)  
NYHA class, n (%)    <0.001 
I 2,014 (19.8) 666 (14.7) 1,348 (24.0)  
II 4,753 (46.7) 2,255 (49.6) 2,498 (44.4)  
III 3,273 (32.2) 1,564 (34.4) 1,709 (30.4)  
IV 130 (1.3) 59 (1.3) 71 (1.3)  
Comorbidity, n (%)     
Diabetes mellitus 2,128 (20.6) 835 (18.1) 1,293 (22.7) <0.001 
Hypertension 4,209 (40.8) 1,338 (29.0) 2,871 (50.4) <0.001 
COPD/ asthma 1,232 (11.9) 503 (10.9) 729 (12.8) 0.003 
Smoker, n (%)    <0.001 
13 
 
ever 3,430 (37.3) 1,702 (40.2) 1,728 (34.6)  
never 5,763 (62.7) 2,534 (59.2) 3,229 (65.4)  
Sodium, mmol/L 139 ± 4 139 ± 4 140 ± 4 0.24 
Potassium, mmol/L 4.4 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 <0.001 
NTproBNP, ng/L 
1,008 
(305-2,605) 
1,046 
(399-2,635) 
991 
(278-2,595) 
0.01 
eGFR, ml/min/1.73m² 67 (49-86) 62 (46-81) 71 (52-90) <0.001 
HF registry, n (%)    <0.001 
Norway 6,122 (59.4) 2,936 (63.6) 3,186 (55.9)  
Heidelberg 2,368 (23.0) 710 (15.4) 1,658 (29.1)  
Hull 1,822 (17.7) 971 (21.0) 851 (14.9)  
HF, heart failure; BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left ventricular 
ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection 
fraction; HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association; COPD, 
chronic obstructive pulmonary disease; NTproBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated 
glomerular filtration rate using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula; . 
Significant p-values are written in italics. 
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Table 4: Treatment of HF patients with respect to time of enrolment into the heart failure 
registries (period 1: 1995-2005, period 2: 2006-2015)  
 All patients  
(n = 10,312) 
Period 1  
(n = 4,617) 
Period 2  
(n = 5,695) 
p-value 
ACEI, n (%) 7,219 (70.0) 3,302 (71.5) 3,917 (68.8) 0.003 
Captopril 174 (2.4) 144 (4.4) 30 (0.8) <0.001 
Enalapril 1,135 (15.7) 679 (20.6) 456 (11.6) <0.001 
Lisinopril 906 (12.6) 600 (18.2) 306 (7.8) <0.001 
Ramipril 4,794 (66.4) 1,753 (53.1) 3,041 (77.6) <0.001 
Trandolapril 12 (0.2) 10 (0.3) 2 (0.0) 0.009 
Other 197 (2.7) 116 (3.5) 81 (1.4) <0.001 
ARB, n (%) 1,915 (18.6) 643 (13.9) 1,272 (22.3) <0.001 
ACEI and/or ARB, n (%) 8,867 (86.0) 3,865 (83.7) 5,002 (87.8) <0.001 
ACEI/ARB dose equivalent, 
% 
50 (25-100) 50 (25-100) 50 (25-100) 0.07 
Beta-blocker, n (%) 8,482 (82.3) 3,486 (75.5) 4,996 (87.7) <0.001 
Bisoprolol 1,425 (16.8) 348 (10.0) 1,077 (21.6) <0.001 
Carvedilol 2,275 (26.8) 1,096 (31.4) 1,179 (23.6) <0.001 
Metoprolol succinate 4,208 (49.6) 1,719 (49.3) 2,489 (49.8) 0.64 
Nebivolol 160 (1.8) 30 (0.9) 130 (2.3) <0.001 
Other  414 (4.9) 293 (8.4) 121 (2.1) <0.001 
Beta-blocker dose 
equivalent, % 
50 (13-75) 25 (4-75) 50 (25-79) <0.001 
MRA, n (%) 3,098 (30.0) 1,247 (27.0) 1,851 (32.5) <0.001 
Loop diuretics, n (%) 7,288 (70.7) 3,555 (77.0) 3,733 (65.5) <0,001 
Loop diuretic dose, mg 
furosemide 
40 (0-80) 40 (20-80) 40 (0-80) <0,001 
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Anticoagulants, n (%) 4,492 (43.6) 2,102 (45.5) 2,390 (42.0) <0.001 
ASA, n (%) 4,411 (42.8) 1,783 (38.6) 2,628 (46.1) <0.001 
Statin, n (%) 5,784 (56.1) 2,260 (48.9) 3,524 (61.9) <0.001 
HF, heart failure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, 
mineralocorticoid receptor antagonist; ASA, Acetylsalicyl acid. Significant p-values are written in italics. 
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Outcome 
Of 10,312 patients included in the three HF registries, 5,297 (51.4%) died during a median 
follow-up of 66 (33-105) months. Of these, 3,836 patients (72.4%) were classified as having 
HFrEF, 957 (18.1%) as having HFmrEF, and 504 (9.5%) as having HFpEF.  Kaplan-Meier 
curves for 10-year survival with respect to type of HF are shown in Figure 1. 
Of 4,617 patients enrolled in period 1, 3,204 (69.4%) died during a median follow-up of 66 
(32-106) months. Of 5,695 patients enrolled in period 2, 2,093 (36.8%) died during a median 
follow-up of 66 (33-105) months. Kaplan-Meier curves for 10-year survival with respect to 
time of enrolment are shown in Figure 2. As presented in Supplemental figure 1, survival of 
HF outpatients gradually increased since 1995. Supplemental figure 2 shows Kaplan-Meier 
curves for 10-year survival with respect to type of HF and time of enrolment. 
1-, 2-, 3-, 4-, and 5-year mortality rates for HF patients with respect to LVEF and time of 
enrolment are presented in Table 5. 
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Table 5: All-cause mortality rates of HF patients with respect to LVEF group and time of enrolment.  
All-
cause 
death 
All 
patients 
(n=10,312) 
Period 1 
(n=4,617) 
Period 2 
(n=5,695) 
HFrEF HFmrEF HFpEF 
All 
patients 
(n=7,080) 
Period 1 
(n=3,325) 
Period 2 
(n=3,755) 
All 
patients 
(n=2,086) 
Period 1 
(n=850) 
Period 2 
(n=1,236) 
All 
patients 
(n=1,146) 
Period 1 
(n=442) 
Period 2 
(n=704) 
1-year  6.1 8.1 4.5 6.8 8.5 5.4 4.1 5.5 3.2 5.4 9.7 2.7 
2-years 13.3 16.8 10.6 14.4 17.6 11.5 10.7 12.9 9.1 11.9  17.9 8.2 
3-years 20.0 24.3 16.5 21.2 25.1 17.7 17.5 20.9 15.1 17.4 25.1 12.5 
4-years 25.9 31.5 21.4 27.5 32.2 23.2 22.7 27.5 19.4 22.4 33.5 15.5 
5-years 31.4 38.2 25.9 33.2 39.0 28.1  27.2 33.3 23.1 27.6 41.2 19.0 
HF, heart failure; LVEF, left ventricular ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with 
preserved ejection fraction; n, number. Figures given represent percentages. 
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In univariable Cox regression analyses of the general sample, a diagnosis of HFmrEF or 
HFpEF was associated with better survival as compared to HFrEF (HR 0.84, 95%-CI 0.78-
0.90, p<0.001 for HFmrEF vs. HFrEF, and HR 0.90, 95%-CI 0.82-0.99, p=0.03 for HFpEF vs. 
HFrEF). Survival was similar in patients with HFmrEF or HFpEF (HR 1.08, 95%-CI 0.97-1.20, 
p=0.15). Survival significantly improved between time periods (HR 0.74, 95%-CI 0.69-0.78, 
p<0.001). This was true irrespective of the HF category (HR 0.76, 95%-CI 0.71-0.81, 
p<0.001 for HFrEF, HR 0.80, 95%-CI 0.70-0.91, p=0.001 for HFmrEF, and HR 0.55, 95%-CI 
0.45-0.66, p<0.001 for HFpEF).  
In multivariable regression analyses of the general sample including all variables that were 
significant in univariable analyses (data not shown), survival was independent of type of HF 
(p=0.34 for HFmrEF vs. HFrEF and p=0.84 for HFpEF vs. HFrEF). However, this was only 
true when NT-proBNP was included in the model. In contrast, survival was better in period 2 
as compared to period 1 irrespective from NT-proBNP concentrations (HR 0.85, 95%-CI 
0.76-0.95, p=0.004). Complete results of multivariable regression analyses are shown in 
Table 6.  
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Table 6: Significant predictors of all-cause mortality in multivariable Cox regression analysis 
in patients with HF (general sample). 
Variable HR 95% CI p-value 
Age, years 1.04 1.03-1.04 <0.0001 
NYHA class, vs. NYHA class I    
II 1.23 1.04-1.46 0.02 
III 1.74 1.46-2.07 <0.0001 
IV 1.90 1.26-2.87 0.002 
Aetiology, non-ischaemic vs. ischaemic 0.82 0.74-0.91 0.0002 
Diabetes mellitus, yes vs. no 1.19 1.06-1.33 0.003 
COPD/ asthma, yes vs. no 1.28 1.11-1.47 0.0007 
Hypertension, yes vs. no 1.18 1.07-1.31 0.001 
logNTproBNP  2.00 1.80-2.22 <0.0001 
eGFR, ml/min/1.73m² 0.996 0.993-0.998 0.002 
Sodium, mmol/l 0.97 0.96-0.99 0.0002 
MRA, yes vs. no 1.18 1.06-1.32 0.004 
Loop diuretic, yes vs. no 1.44 1.26-1.65 <0.0001 
Time of enrolment, period 2 vs. period 1 0.85 0.76-0.95 0.004 
HF, heart failure; HR, hazard ratio; CI, confidence interval; HR, heart rate; NYHA, New York Heart Association 
functional class; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate using 
the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula; MRA, mineralocorticoid receptor 
antagonist. Non-significant covariates were body mass index, sex, heart rate, sinus rhythm (yes vs. no), smoker 
(ever vs. never), potassium level, use of angiotensin converting enzyme inhibitors/ angiotensin receptor blockers, 
use of beta blockers, use of statins, use of aspirin, use of anticoagulants, left ventricular ejection fraction 
category. 
 
Significant predictors of all-cause mortality differed between HF categories. Results from 
multivariable analyses in subgroups of patients with HFrEF, HFmrEF or HFpEF are depicted 
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in Supplemental Tables 5-7. Supplemental Tables 8-9 show results from multivariable 
analyses in subgroups with respect to time to enrolment.  
 
Discussion 
Chronic HF is a major cause of serious morbidity and mortality in Europe [1, 7, 8]. In the 
present manuscript, we present a comprehensive dataset including baseline characteristics 
and long-term follow-up of ambulatory patients with chronic HF from three different European 
countries.  
We found that patients stratified by categories of LVEF and/or time of enrolment differ with 
respect to baseline variables including demography, clinical presentation, cause of HF, co-
morbidities and medical treatment. However, long-term survival was independent of HF 
category, whereas it was significantly better in patients enrolled in period 2 as compared to 
period 1.  
The majority of patients presented with HFrEF, while only few patients were classified as 
having HFpEF. Although the number of patients with a diagnosis of HFpEF increased over 
time, HFpEF was less frequent as compared to data from community-based studies. 
However, the proportion of HFpEF was similar to that reported from the ESC-HF-LT Registry 
– suggesting that HFpEF patients rarely present at specialized HF outpatient clinics [3, 11]. 
18.9% of patients had HFmrEF, which is similar to other estimates of the prevalence of 
HFmrEF in the overall HF population [2]. 
As with previous studies, patients with HFrEF were predominantly male and more likely to 
suffer from symptomatic HF of ischaemic origin than patients presenting with HFpEF [2, 3, 5, 
11, 12, 13, 14, 15, 16, 17, 18]. This was true for the entire study duration. Our data also 
confirm the high prevalence of hypertension in the HFpEF population. Clinical characteristics 
of HFmrEF were intermediate between those of HFrEF and HFpEF for some important 
variables including sex distribution, comorbidities, NT-proBNP levels and renal function. 
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However, the proportion of ischaemic HF in HFmrEF was comparable to that in HFrEF, 
suggesting that HFmrEF may represent early-stage or recovered HFrEF [2, 3, 5, 12]. Similar 
results have been reported from clinical trial and registry cohorts [2, 3, 5, 15]. 
In contrast to a number of previous studies describing higher age of patients with HFpEF [2, 
3, 5, 11, 12, 13, 14, 15, 16, 17, 18], we found no clinically significant differences in mean age 
between HF categories. However, patients with HFpEF enrolled in period 2 were ten years 
younger as compared to those enrolled in period 1. In addition, sinus rhythm was more 
common in period 2, and NT-proBNP concentrations were significantly lower. Thus, patients 
with a diagnosis of HFpEF differed substantially between periods, and it may be questioned 
whether the diagnosis “HFpEF” was correct in all cases. The majority of patients with HFrEF 
received guideline-recommended treatment with ACEIs/ARBs and beta-blockers, and one 
third additionally used MRAs. Although there is a lack of evidence for their use in HFmrEF 
and HFpEF, these medications were also used in a substantial proportion of patients with 
LVEF >40%. A similar finding has been reported from the ESC-HF-LT Registry as well as 
from a recently published prospective longitudinal study [3, 5]. The proportion of patients 
taking ACEIs/ARBs and beta-blockers increased irrespective of HF category over time. 
When comparing the proportion of patients with guideline-recommended medical HFrEF 
treatment in the present study to other Western European HF cohorts of the respective time 
periods, a similar [3, 5, 15, 19, 20] or higher [13, 14, 21, 22, 23, 24] rate of adequate HFrEF 
treatment can be noted. This may be explained by the enrolment of stable HF patients in 
specialized HF outpatient clinics (in contrast to primary care settings).  
All-cause mortality of the complete patient sample was 6.1% after one year and increased to 
31.4% after five years. One-year mortality was similar to that observed in other European HF 
registries (5.9-8.1%) but lower when compared to a Spanish cohort study of ambulatory HF 
patients (10%) [3, 27, 28]. Five-year mortality was substantially lower when compared to the 
Danish National Patient Registry [29], retrospective data from Sweden [30] or a recent 
analysis of the Get With The Guidelines-HF (GWTG-HF) registry (43-75.4%) [4]. Of note, all 
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of these studies included patients with acute HF and thus refer to populations that differ from 
the present study.  
Mortality rates significantly decreased over time irrespective from the type of HF. A similar 
trend has been reported from the Danish National Patient Registry with a decline in one- to 
five-year-mortality from 59% during 1983-1987 to 43% during 2008-2013 [29]. In addition, HF 
age-standardized death rates have significantly decreased in seven European countries from 
1987 to 2008 [6].  
Crude mortality rates were higher in HFrEF as compared to HFmrEF and HFpEF. Thus, 
although patients with HFmrEF have many features more typical of HFrEF, their outcome 
resembles those of the HFpEF group more closely than those of the HFrEF group. A similar 
finding has been reported from the ESC-HF-LT Registry [3] and the CHARM trial [16]. After 
adjustment for significant covariates, however, survival of HF patients was independent from 
HF category. This finding is supported by several studies including the GWTG-HF registry [4, 
5, 11, 14, 18]. In contrast, a meta-analysis of 31 studies [17] reported a lower risk for death 
within one year in patients with HFpEF as compared to those with HFrEF. Of note, the meta-
analysis did only adjust for a selected number of covariates including gender, age, ischaemic 
aetiology, hypertension, diabetes and atrial fibrillation. In a recently published study including 
HF patients from New Zealand and Singapore, it was demonstrated that NT-proBNP is a 
major confounder of mortality in HFmrEF and HFpEF: While patients with HFmrEF or HFpEF 
had a lower risk of death than those with HFrEF after adjusting for age, sex, and clinical risk 
factors, the risk of death for any HF phenotype was similar at a given level of NT-proBNP [5]. 
In accordance with this observation, NT-proBNP removed the crude differences in mortality 
between the LVEF categories in our study. NT-proBNP measurements thus provide a critical 
tool for clinicians to risk stratify their HF patients and seem to be of greater importance for 
outcomes than LVEF.  
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Limitations 
The study population comprised only patients seen at HF outpatient clinics and did not 
include hospitalized patients or patients seen in a primary care setting, which may entail 
selection bias. The majority of HF patients, however, are followed at outpatients clinics. 
Therefore, outcome data on this population are important to inform clinical decisions.  
In 2016, the ESC HF guidelines have introduced elevated levels of cardiac peptides as a 
requirement for the diagnosis of HFmrEF or HFpEF [1]. As patients in the present manuscript 
were enrolled between 1995 and 2015, cardiac peptide measurements were not available in 
all patients, and elevated cardiac peptide levels were not required for the diagnosis of 
HFmrEF or HFpEF. In addition, as the assessment of LVEF was not standardized, it may 
have been subject to variations among different operators. Both aspects may have resulted 
in the misclassification of some patients. Some patients may have navigated between 
categories of HF during the time of the study, and we do not have data to assess these 
patients separately. Our study includes patients from three different registries that were 
initiated independently from one another. However, the consistency of patient selection is 
warranted by inclusion of ambulatory patients with chronic stable HF after stabilization of 
clinical status and optimization of medical treatment. Moreover, the large sample size and 
prospective inclusion of patients from three European countries over a long time period are 
obvious strengths of the present study. 
 
Conclusion 
Chronic ambulatory HF patients stratified by categories of LVEF differ with respect to 
baseline variables including demography, clinical presentation, cause of HF, co-morbidities 
and medical treatment. Patients with HFmrEF share many clinical features with those with 
HFrEF. Crude mortality rates of patients with HFmrEF, however, resemble those of the 
HFpEF group more closely than those of the HFrEF group. After adjusting for a wide range of 
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covariates including NT-proBNP, long-term survival was independent from LVEF category. 
Survival significantly improved during the last two decades irrespective from type of HF. 
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Figures 
Figure 1: Kaplan-Meier curves for 10-year survival of HF outpatients with respect to type of 
HF. 
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure 
with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction. 
 
Figure 2: Kaplan-Meier curves for 10-year survival of HF outpatients with respect to time of 
enrollment. 
HF, heart failure. 
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Supplemental material 
Supplemental table 1: Distribution of HF categories in the three registries 
HF registry 
All patients  
(n = 10,312) 
HFrEF  
(n = 7,080) 
HFmrEF  
(n = 2,086) 
HFpEF 
(n = 1,146) 
p-value 
Norway 6,122 (59.4) 
4,561 
74.5) 
998 (16.3) 563 (9.2) <0.001 
Heidelberg 2,368 (23.0) 
1,385 
(58.5) 
526 (22.2) 457 (19.3) <0.001 
Hull 1,822 (17.7) 
1,134 
(62.2) 
562 (30.8) 126 (6.9) <0.001 
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection 
fraction; HFpEF, heart failure with preserved ejection fraction 
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Supplemental table 2: Baseline characteristics of HFrEF patients with respect to time of 
enrolment. 
 HFrEF (n = 7,080) 
p-value 
Period 1 (n = 3,325) Period 2 (n = 3,755) 
Age, years 67.4 ± 12.2 65.9 ± 12.9 <0.001 
Female, n (%) 763 (22.9) 911 (24.3) 0.19 
BMI, kg/m² 26.7 ± 4.9 27.2 ± 5.5 0.001 
SBP, mmHg 124 ± 22 123 ± 21 0.001 
HR, 1/min 71 ± 15 70 ± 14 0.01 
Sinus rhythm, n (%) 1,995 (69.9) 2,434 (66.6) 0.006 
LVEF, % 27 ± 7 28 ± 7 0.006 
Cause of HF, n (%)   <0.001 
ischaemic 1,902 (63.3) 1,879 (53.6)  
non-ischaemic 1,105 (36.7) 1,626 (46.4)  
NYHA class, n (%)   <0.001 
I 434 (13.2) 716 (19.3)  
II 1,627 (49.6) 1,727 (46.6)  
III 1,171 (35.7) 1,207 (32.6)  
IV 46 (1.4) 57 (1.4)  
Comorbidity, n (%)    
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Diabetes mellitus 585 (17.6) 873 (23.4) <0.001 
Hypertension 888 (26.8) 1,707 (45.8) <0.001 
COPD/ asthma 366 (11.0) 519 (13.9) <0.001 
Smoker, n (%)   <0.001 
ever 1,286 (41.7) 999 (31.5)  
never 1,795 (58.3) 2,175 (68.5)  
Sodium, mmol/L 139 ± 5 139 ± 4 0.16 
Potassium, mmol/L 4.4 ± 0.5 4.4 ± 0.5 0.03 
NTproBNP, ng/L 1,277 (496-3,002) 1,311 (482-3,205) 0.92 
eGFR, ml/min/1.73m² 62 (46-81) 69 (51-87) <0.001 
Treatment    
ACEI, n (%) 2,450 (73.7) 2,681 (71.6) 0.14 
Captopril 115 (4.7) 23 (0.9) <0.001 
Enalapril 499 (20.4) 337 (12.6) <0.001 
Lisinopril 421 (17.2) 216 (8.1) <0.001 
Ramipril 1,324 (54.0) 2,053 (76.6) <0.001 
Trandolapril 6 (0.2) 2 (0.0) 0.12 
Other 84 (3.4) 49 (1.8) <0.001 
ARB, n (%) 456 (13.8) 848 (22.7) <0.001 
ACEI and/or ARB, n 2,842 (85.8) 3,389 (90.8) <0.001 
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(%) 
ACEI/ARB dose 
equivalent, % 
75 (50-100) 63 (50-100) 0.04 
Beta-blocker, n (%) 2,573 (77.5) 3,419 (91.2) <0.001 
Bisoprolol 245 (9.5) 698 (20.4) <0.001 
Carvedilol 888 (34.5) 840 (24.6) <0.001 
Metoprolol 
succinate 
1,234 (48.0) 1,755 (51.3) 0.01 
Nebivolol 23 (0.9) 60 (1.8) 0.007 
Other  183 (7.1) 66 (1.9) <0.001 
Beta-blocker dose 
equivalent, % 
50 (25-100) 50 (25-100) <0.001 
MRA, n (%) 977 (29.4) 1,383 (37.0) <0.001 
Loop diuretics, n (%) 2,629 (79.1) 2,758 (73.5) <0.001 
Loop diuretic dose, mg 
furosemide 
40 (40-80) 40 (40-80) <0.001 
Anticoagulants, n (%) 1,558 (46.9) 1,713 (45.7) 0.33 
ASA, n (%) 1,283 (38.6) 1,780 (47.5) <0.001 
Statin, n (%) 1,663 (50.1) 2,375 (63.4) <0.001 
HF registry, n (%)   <0.001 
Norway 2,449 (65.2) 2,112 (63.5)  
5 
 
Heidelberg 833 (22.2) 552 (16.6)  
Hull 473 (12.6) 661 (19.9)  
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; period 1, 1995-2005; period 2, 2006-
2015; BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; NTproBNP, 
N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate using the CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) formula; ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; ASA, 
Acetylsalicyl acid. Significant p-values are written in italics. 
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Supplemental table 3: Baseline characteristics of HFmrEF patients with respect to time of 
enrolment. 
 HFmrEF (n = 2,086) 
p-value 
Period 1 (n = 850) Period 2 (n = 1,236) 
Age, years 69.2 ± 12.6 65.9 ± 14.9 <0.001 
Female, n (%) 269 (31.6) 341 (27.6) 0.04 
BMI, kg/m² 27.8 ± 5.7 27.9 ± 5.3 0.64 
SBP, mmHg 132 ± 24 127 ± 22 <0.001 
HR, 1/min 70 ± 14 69 ± 14 0.42 
Sinus rhythm, n (%) 512 (68.5) 775 (65.1) 0.11 
LVEF, % 43 ± 3 43 ± 3 0.04 
Cause of HF, n (%)   <0.001 
ischaemic 483 (60.7) 584 (46.4)  
non-ischaemic 313 (39.3) 598 (53.6)  
NYHA class, n (%)   <0.001 
I 162 (19.4) 374 (30.5)  
II 433 (51.9) 511 (41.7)  
III 231 (27.7) 329 (26.9)  
IV 8 (1.0) 11 (0.9)  
Comorbidity, n (%)    
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Diabetes mellitus 172 (20.3) 284 (23.0) 0.13 
Hypertension 289 (34.0) 678 (54.9) <0.001 
COPD/ asthma 92 (10.8) 137 (11.1) 0.84 
Smoker, n (%)   0.75 
ever 317 (40.9) 471 (41.6)  
never 459 (59.1) 662 (58.4)  
Sodium, mmol/L 140 ± 3 139 ± 3 0.06 
Potassium, mmol/L 4.4 ± 0.5 4.3 ± 0.4 0.002 
NTproBNP, ng/L 667 (208-1,610) 638 (175-1,839) 0.76 
eGFR, ml/min/1.73m² 62 (46-81) 73 (53-91) <0.001 
Treatment    
ACEI, n (%) 587 (69.1) 843 (68.4) 0.71 
Captopril 18 (3.1) 3 (0.4) <0.001 
Enalapril 100 (17.0) 78 (9.3) <0.001 
Lisinopril 133 (22.7) 64 (7.6) <0.001 
Ramipril 312 (53.2) 673 (79.8) <0.001 
Trandolapril 4 (0.7) 0 (0.0) 0.02 
Other 20 (3.4) 25 (2.9) 0.64 
ARB, n (%) 114 (13.4) 262 (21.3) <0.001 
ACEI and/or ARB, n 689 (81.1) 1,074 (87.5) <0.001 
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(%) 
ACEI/ARB dose 
equivalent, % 
50 (50-100) 50 (50-100) 0.74 
Beta-blocker, n (%) 626 (73.6) 1,036 (84.0) <0.001 
Bisoprolol 77 (12.3) 243 (23.5) <0.001 
Carvedilol 144 (23.0) 247 (23.8) 0.70 
Metoprolol 
succinate 
311 (49.7) 472 (45.6) 0.10 
Nebivolol 5 (0.8) 37 (3.6) <0.001 
Other  89 (14.2) 37 (3.6) <0.001 
Beta-blocker dose 
equivalent, % 
50 (25-75) 50 (25-100) 0.36 
MRA, n (%) 169 (19.9) 339 (27.6) <0.001 
Loop diuretics, n (%) 589 (69.3) 677 (54.8) <0.001 
Loop diuretic dose, mg 
furosemide 
40 (40-80) 40 (40-80) 0.55 
Anticoagulants, n (%) 323 (38.0) 467 (37.8) 0.94 
ASA, n (%) 369 (43.4) 567 (45.9) 0.25 
Statin, n (%) 425 (50.0) 784 (63.5) <0.001 
HF registry, n (%)   <0.001 
Norway 497 (58.5) 501 (40.5)  
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Heidelberg 95 (11.2) 431 (34.9)  
Hull 258 (30.4) 304 (24.6)  
HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; period 1, 1995-2005; period 2, 
2006-2015; BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left ventricular 
ejection fraction; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; 
NTproBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate using the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; ASA, 
Acetylsalicyl acid. Significant p-values are written in italics. 
 
  
10 
 
Supplemental table 4: Baseline characteristics of HFpEF patients with respect to time of 
enrolment. 
 HFpEF (n = 1,146) 
p-value 
Period 1 (n = 442) Period 2 (n = 704) 
Age, years 72.0 ± 13.1 62.0 ± 17.7 <0.001 
Female, n (%) 181 (40.9) 273 (38.8) 0.01 
BMI, kg/m² 26.4 ± 5.5 27.4 ± 5.2 0.004 
SBP, mmHg 131 ± 23 126 ± 21 <0.001 
HR, 1/min 71 ± 14 68 ± 13 <0.001 
Sinus rhythm, n (%) 212 (57.9) 477 (72.8) <0.001 
LVEF, % 58 ± 8 57 ± 5 0.002 
Cause of HF, n (%)   <0.001 
ischaemic 148 (35.9) 165 (24.2)  
non-ischaemic 264 (64.1) 518 (75.8)  
NYHA class, n (%)   <0.001 
I 70 (16.2) 258 (37.2)  
II 195 (45.1) 260 (37.5)  
III 162 (37.5) 173 (24.9)  
IV 5 (1.2) 3 (0.4)  
Comorbidity, n (%)    
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Diabetes mellitus 78 (17.7) 136 (19.4) 0.49 
Hypertension 161 (26.6) 486 (69.2) <0.001 
COPD/ asthma 45 (10.2) 73 (10.4) 0.93 
Smoker, n (%)   <0.001 
ever 99 (26.1) 258 (39.7)  
never 280 (73.9) 392 (60.3)  
Sodium, mmol/L 139 ± 3 140 ± 3 0.07 
Potassium, mmol/L 4.4 ± 0.5 4.3 ± 0.4 <0.001 
NTproBNP, ng/L 467 (224-1,489) 281 (90-1,184) 0.01 
eGFR, ml/min/1.73m² 59 (44-75) 81 (56-98) <0.001 
Treatment    
ACEI, n (%) 265 (59.9) 393 (55.9) 0.19 
Captopril 11 (4.1) 4 (1.0) 0.04 
Enalapril 80 (30.2) 41 (10.4) <0.001 
Lisinopril 46 (17.4) 26 (6.6) <0.001 
Ramipril 117 (44.2) 315 (80.2) <0.001 
Trandolapril 0 (0.0) 0 (0.0) n.a. 
Other 11 (4.1) 7 (1.8) 0.07 
ARB, n (%) 72 (16.3) 162 (23.1) 0.005 
ACEI and/or ARB, n 334 (75.6) 539 (76.9) 0.61 
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(%) 
ACEI/ARB dose 
equivalent, % 
50 (50-100) 50 (50-100) 0.22 
Beta-blocker, n (%) 287 (65.1) 541 (77.2) 0.04 
Bisoprolol 26 (9.1) 136 (25.1) <0.001 
Carvedilol 64 (22.6) 92 (17.0) 0.06 
Metoprolol 
succinate 
174 (60.6) 262 (48.4) 0.001 
Nebivolol 2 (0.7) 33 (6.1) <0.001 
Other  21 (7.3) 18 (3.3) 0.01 
Beta-blocker dose 
equivalent, % 
50 (25-75) 50 (25-75) 0.77 
MRA, n (%) 101 (22.9) 129 (18.3) 0.06 
Loop diuretics, n (%) 337 (76.2) 298 (42.3) <0.001 
Loop diuretic dose, mg 
furosemide 
40 (40-80) 40 (40-80) 0.20 
Anticoagulants, n (%) 221 (50.0) 210 (29.9) <0.001 
ASA, n (%) 131 (29.6) 281 (40.0) <0.001 
Statin, n (%) 172 (38.9) 365 (52.0) <0.001 
HF registry, n (%)   <0.001 
Norway 327 (73.9) 236 (33.5)  
13 
 
Heidelberg 63 (14.3) 394 (56.0)  
Hull 52 (11.8) 74 (10.5)  
HF, heart failure; HFpEF, heart failure with preserved ejection fraction; period 1, 1995-2005; period 2, 
2006-2015; BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; LVEF, left ventricular 
ejection fraction; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; 
NTproBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate using the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; ASA, 
Acetylsalicyl acid. Significant p-values are written in italics. 
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Supplemental table 5: Significant predictors of all-cause mortality in multivariable Cox 
regression analysis in patients with HFrEF. 
Variable HR 95% CI p-value 
Age, years 1.04 1.04-1.05 <0.0001 
NYHA class, vs. NYHA class I    
III 1.49 1.33-1.68 <0.0001 
IV 1.71 1.12-2.59 0.01 
Aetiology, non-ischaemic vs. ischaemic 0.75 0.66-0.85 <0.0001 
Diabetes mellitus, yes vs. no 1.24 1.09-1.41 0.001 
COPD/ asthma, yes vs. no 1.45 1.24-1.69 <0.0001 
Hypertension, yes vs. no 1.13 1.01-1.27 0.03 
logNTproBNP 1.95 1.74-2.20 <0.0001 
Sodium, mmol/l 0.97 0.96-0.99 0.001 
Loop diuretic, yes vs. no 1.31 1.12-1.52 0.0007 
Anticoagulants, yes vs. no 1.12 1.00-1.26 0.05 
Time of enrolment, period 2 vs. period 1 0.85 0.76-0.97 0.01 
HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; CI, confidence interval; NYHA, New York 
Heart Association functional class; COPD, chronic obstructive pulmonary disease. Significant p-values are 
written in italics. 
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Supplemental table 6: Significant predictors of all-cause mortality in multivariable Cox 
regression analysis in patients with HFmrEF. 
Variable HR 95% CI p-value 
Age, years 1.03 1.02-1.04 <0.0001 
NYHA class III, vs. NYHA class I 1.40 1.12-1.76 0.003 
Hypertension, yes vs. no 1.27 1.03-1.57 0.03 
logNTproBNP 2.34 1.87-2. 92 <0.0001 
Loop diuretic, yes vs. no 1.93 1.49-2. 52 <0.0001 
Sodium, mmol/L 0.97 0.94-0.99 0.03 
HFmrEF, heart failure with mid-range ejection fraction; HR, hazard ratio; CI, confidence interval; NYHA, New 
York Heart Association functional class. Significant p-values are written in italics. 
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Supplemental table 7: Significant predictors of all-cause mortality in multivariable Cox 
regression analysis in patients with HFpEF. 
Variable HR 95% CI p-value 
Age, years 1.04 1.01-1.06 0.002 
NYHA class, vs. NYHA class I    
II 1.88 1.01-3.51 0.05 
III 3.09 1.64-5.84 0.0005 
Potassium, mmol/L 1.55 1.02-2.37 0.04 
logNT-proBNP 2. 50 1.72-3.62 <0.0001 
Loop diuretic, yes vs. no 2.48 1.48-4.13 0.0005 
Anticoagulants, yes vs. no 0.67 0.45-0.99 0.05 
HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; CI, confidence interval; NYHA, New York 
Heart Association functional class. Significant p-values are written in italics. 
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Supplemental table 8: Significant predictors of all-cause mortality in multivariable Cox 
regression analysis in patients with HF enrolled in period 1. 
Variable HR 95% CI p-value 
Age, years 1.05 1.04-1.06 <0.0001 
LVEF, % 0.99 0.98-0.99 0.007 
Aetiology, non-ischaemic vs. ischaemic 0.84 0.70-0.99 0.05 
NYHA class III, vs. NYHA class I 1.21 1.02-1.45 0.03 
Hypertension, yes vs. no 1.21 1.03-1.42 0.02 
COPD/ asthma, yes vs. no 1.43 1.11-1.83 0.005 
Diabetes, yes vs. no 1.21 1.00-1.46 0.05 
logNTproBNP 1.83 1.57-2.15 <0.0001 
MRA, yes vs. no 1.23 1.03-1.48 0.03 
Loop diuretic, yes vs. no 1.42 1.16-1.74 0.0008 
HF, heart failure; HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New 
York Heart Association functional class; COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid 
receptor antagonist. Significant p-values are written in italics. 
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Supplemental table 9: Significant predictors of all-cause mortality in multivariable Cox 
regression analysis in patients with HF enrolled in period 2. 
Variable HR 95% CI p-value 
Age, years 1.03 1.03-1.04 <0.0001 
Sex, female vs. male 0.73 0.64-0.84 <0.0001 
BMI, kg/m² 0.98 0.97-0.99 0.02 
NYHA class, vs. NYHA class I    
II 1.26 1.01-1.57 0.04 
III 2.02 1.61-2.53 <0.0001 
IV 3.40 1.98-5.83 <0.0001 
Aetiology, non-ischaemic vs. ischaemic 0.85 0.75-0.97 0.01 
Diabetes mellitus, yes vs. no 1.26 1.10-1.44 0.0009 
COPD/ asthma, yes vs. no 1.26 1.07-1.48 0.005 
logNTproBNP 1.96 1.72-2.24 <0.0001 
eGFR, ml/min/1.73m² 0.996 0.993-0.999 0.02 
Sodium, mmol/l 0.97 0.95-0.98 0.0001 
Loop diuretic, yes vs. no 1.51 1.27-1.80 <0.0001 
HF, heart failure; HR, hazard ratio; CI, confidence interval; BMI, body mass index; NYHA, New York Heart 
Association functional class; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula. Significant p-
values are written in italics.  
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Supplemental figure 1: Kaplan-Meier curves for 5-year survival of HF outpatients stratified 
by two-year enrolment periods. 
 
HF, heart failure. 
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Supplemental figure 2: Kaplan-Meier curves for 10-year survival of HF outpatients with 
respect to type of HF and time of enrolment. 
 
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure 
with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction. 
 
